FDA: Gout Drug Linked to Increased Risk of Heart-Related Death

By November 15, 2017

The FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009.

Duzallo Now Available for the Treatment of Uncontrolled Gout

By October 10, 2017

The fixed-dose product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.

Uloric Dosing Updated to Include Patients with Severe Renal Impairment

By September 27, 2017

The new labeling now recommends patients with severe renal impairment be limited to a dose of 40mg once daily.

Fixed-Dose Combo Tx Duzallo Approved for Uncontrolled Gout

By August 21, 2017

This fixed-dose combination product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.

Drug Combo Effective for Tophaceous Gout

By June 09, 2017

When lesinurad 400mg was added to febuxostat, significantly more patients achieved target sUA by Month 6 (76.1%; P<0.0001) vs. febuxostat alone (46.8%); however, this was not seen with adding lesinurad 200mg (56.6%; P=0.13).

Recall: CV Meds Found to Contain Gout Pills

By May 26, 2017

Accidental patient dosing with Zurampic can potentially cause adverse renal effects such as acute renal failure; this is more common if Zurampic is given alone without a xanthine oxidase inhibitor.

Do Uric Acid Lowering Drugs Reduce BP in Hypertensive Patients?

By April 14, 2017

In general, there was low quality evidence from three trials indicating no reduction in systolic (-6.2mmHg, 95% CI: -12.8 to 0.5) or diastolic (-3.9mmHg, 95% CI: -9.2 to 1.4) 24-hour ambulatory BP with uric acid lowering drugs vs. placebo.

Dual-Mechanism Gout Treatment Under FDA Review

By January 04, 2017

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Duzallo (lesinurad/allopurinol fixed-dose combination; Ironwood) for the treatment of hyperuricemia in patients with uncontrolled gout.

Review Finds Gout Therapy Monitoring 'Suboptimal' Among Veterans

By December 07, 2016

A retrospective chart review found that rates of urate-lowering therapy monitoring among United States veterans with gout were less than optimal. The full findings are published in the Annals of Pharmacotherapy.

Effects of DASH Diet on Serum Uric Acid Levels Explored

December 05, 2016

Greatest decrease in those with hyperuricemia; increasing sodium intake linked to drop in serum UA

Allopurinol Skin Reactions in Gout Might Predict Febuxostat Reactions

By November 14, 2016

Use of febuxostat (FBX) might cause skin reactions in some patients with gout who have experienced such reactions after allopurinol administration.

Review Looks at Effective Treatments for Gout Management

By November 02, 2016

A treatment review for acute gout attacks and management has found strong evidence that colchicine, NSAIDs, and corticosteroids are effective in relieving pain in acute gout patients.

New Oral Treatment for Uncontrolled Gout Available

By October 03, 2016

Zurampic is now available for combination use with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

Can Lesinurad Added to Allopurinol Lower Serum Urate in Gout Patients?

By August 31, 2016

Adding lesinurad to allopurinol provided extra benefit vs. allopurinol alone in lower serum urate (sUA) levels and is an option for patients requiring additional urate-lowering, a study published in Arthritis & Rheumatology reported.

DASH Diet May Benefit Gout Patients

By August 15, 2016

A study published in Arthritis & Rheumatology has found that the DASH diet reduced serum uric acid, particularly in patients with hyperuricemia.

Gout Flares With Arhalofenate Vs Allopurinol Examined in Study

August 15, 2016

Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology.

Gout Management Updates Reflect New Treatments

July 26, 2016

The European League Against Rheumatism (EULAR) have updated their recommendations on the management of gout to reflect novel treatments and evidence surrounding already established treatments.

Higher Allopurinol Dose May be Nephroprotective in Elderly

By June 17, 2016

A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases.

Case: Post-Op Gouty Arthritis Secondary to HCTZ Use

April 19, 2016

A case of postoperative acute gouty arthritis following laparoscopic cholecystectomy with umbilical hernioplasty, secondary to hydrochlorothiazide use.

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

By April 14, 2016

Findings from a new study published in Seminars in Arthritis and Rheumatism show significant racial disparities in the risk of gout patients developing a serious, sometimes fatal adverse reaction to urate-lowering drugs.

REMS Requirement Removed for Gout Drug

By April 13, 2016

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Krystexxa (pegloticase; Horizon) Injection.

Febuxostat vs. Allopurinol for the Prevention of Tumor Lysis Syndrome

By March 28, 2016

The efficacy and safety of febuxostat was noninferior to allopurinol for preventing tumor lysis syndrome (TLS) in patients with malignant tumors about to receive chemotherapy, according to a new study published in the journal, Oncology.

Gout Drug Effective in Patients With Renal Impairment

By March 02, 2016

Treatment with febuxostat was effective and well tolerated in gout patients with moderate to severe renal impairment, findings from a study published in Arthritis and Rheumatology stated.

Steroid May Have Similar Analgesic Efficacy for Acute Gout as Current Rx

February 24, 2016

For patients with acute gout, prednisolone has similar analgesic effectiveness to indomethacin, according to a study published online February 23 in the Annals of Internal Medicine.

Study Shows Majority of Gout Patients Unaware of Treatment Goals

By January 22, 2016

A new study has highlighted a possible knowledge-gap between healthcare professionals and gout patients, concerning their condition.

New Gout Treatment Gets FDA Approval

By December 23, 2015

The FDA has approved Zurampic (lesinurad; AstraZeneca) to treat hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI).

Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Flares?

By November 11, 2015

Dietary omega-3 fatty acid-rich fish consumption, but not omega-3 supplements alone, confer a protective effect against recurrent gout attacks, reported MaryAnn Zhang, MD, from the Boston University School of Medicine, Boston, MA, at the 2015 ACR/ARHP Annual Meeting.

Analysis: No Cardiovascular Benefits for Xanthine Oxidase Inhibitors

By November 10, 2015

Xanthine oxidase inhibitors (XOIs) do not improve uric acid-associated risks for cardiovascular events or deaths among adults, according to a meta-analysis of data pooled from 61 randomized controlled clinical studies, which was reported at the 2015 ACR/ARHP Annual Meeting.

Colchicine May Prevent Acute Cardiovascular Events in Gout Patients

By November 10, 2015

In patients with gout, chronic colchicine use has no effect on the rate of incident coronary artery disease (CAD), a study presented at the 2015 ACR/ARHP Annual Meeting concluded.

Canakinumab Effective for Long-term Management of Acute Gouty Arthritis Flares

By November 10, 2015

The selective human anti-interleukin-1β antibody canakinumab demonstrates long-term safety and efficacy for patients with acute gouty arthritis flares, according to a follow-up study reported at the 2015 ACR/ARHP Annual Meeting.